Table 2 Randomized phase II clinical trials in oestrogen receptor-positive metastatic breast cancer
From: New targets for therapy in breast cancer: Farnesyltransferase inhibitors
Combination | Clinical setting | Number of patients | Primary end-point | Trial group |
|---|---|---|---|---|
Letrozole ± tipifarnib | 2nd line | 108 | ORR | J&J-INT-22 |
Letrozole ± tipifarnib | 1st/2nd line | 100+ | ORR | CALGB |
Anastrazole ± lonarfarnib | 1st line | 110 | ORR | Schering |